22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The current state of retinopathy of prematurity in India, Kenya, Mexico, Nigeria, Philippines, Romania, Thailand, and Venezuela

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Retinopathy of prematurity (ROP) is one of the leading causes of preventable blindness in children worldwide. Middle-income nations are currently experiencing epidemic levels of ROP, because greater access to neonatal intensive care units has improved survival rates of premature infants, but without sophisticated oxygen regulation. The epidemiology, screening infrastructure, treatment options, and challenges that these countries face are often tied to unique local socioeconomic, cultural, geopolitical, and medical factors. We present an overview and narratives of the current state of ROP in eight countries that are or soon will be experiencing ROP epidemics—India, Kenya, Mexico, Nigeria, Phillipines, Romania, Thailand, and Venezuela—with a view to fostering both an understanding of the differences in the ROP landscape in various settings and an interest in the further development of ROP screening and treatment services tailored to local requirements.

          Related collections

          Author and article information

          Journal
          Digit J Ophthalmol
          Digit J Ophthalmol
          Digital Journal of Ophthalmology : DJO
          Massachusetts Eye and Ear Infirmary
          1542-8958
          April 2019
          12 October 2019
          : 25
          : 4
          : 49-58
          Affiliations
          [a ]Retina Service, Mass Eye & Ear, Harvard Medical School, Boston;
          [b ]Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston;
          [c ]Department of Ophthalmology, University of Nairobi, College of Health Sciences;
          [d ]Department of Ophthalmology, University of Ilorin and University of Ilorin Teaching Hospital, Ilorin, Nigeria;
          [e ]Department of Ophthalmology, Queen Sirikit National Institute of Child Health, Bangkok, Thailand;
          [f ]Retina Service, St. Luke’s Medical Center, Manila, Phillipines;
          [g ]Retina and Vitreous Department, Asociación para Evitar la Ceguera en Mexico, “Hospital Luis Sanchez Bulnes,” IAP, Mexico City, Mexico;
          [h ]Calabar Childrens Eye Center, Department of Ophthalmology, University of Calabar, Calabar, Nigeria;
          [i ]Department of Ophthalmology, Hospital Pediatrico Dr. Agustin Zubillaga, Barquisimeto, Venezuela;
          [j ]Retina Service, L.V. Prasad Eye Institute, Bhubaneswar, India;
          [k ]Marie Sklodowska Curie Children’s Clinical Hospital, Bucharest, Romania;
          [l ]Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;
          [m ]Department of Ophthalmology, University of Illinois Chicago School of Medicine, Chicago;
          [n ]Casey Eye Institute, Oregon Health & Sciences University, Portland;
          [o ]Mid Atlantic Retina, Wills Eye Hospital, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia
          Author notes
          [*]

          These authors contributed equally to this work as first authors.

          Funding/support: Research to Prevent Blindness, New York, NY (RVPC). This project was supported by grants K12EY027720 and P30EY10572 from the National Institutes of Health, Bethesda, MD (JPC); by grants SCH-1622679 from the National Science Foundation, Arlington, VA (JPC); and by unrestricted departmental funding and a Career Development Award from Research to Prevent Blindness, New York, NY (JPC). Funding organizations had no role in the design of conduct of this project.

          Disclosures: Consultant for Alcon (RVPC, YY), Allergan (RVPC), Bausch & Lomb Surgical (RVPC), Visunex Medical Systems (RVPC).

          Correspondence: Yoshihiro Yonekawa 840 Walnut Street, Philadelphia, PA 19107 (email: yyonekawa@ 123456midatlanticretina.com ).
          Article
          PMC7001648 PMC7001648 7001648 djo-19-049
          10.5693/djo.01.2019.08.002
          7001648
          32076388
          65f4fb96-c203-41c1-b48f-20de6083a7af
          Copyright ©2019. All rights reserved. Reproduction in whole or in part in any form or medium without expressed written permission of the Digital Journal of Ophthalmology is prohibited.
          History
          Categories
          Review

          Comments

          Comment on this article